




# **Ischemic stroke complicating TAVI: Predictors, prevention and management**


**Israel Barbash, MD**

**Sheba Medical Center, Israel**

# Real-life stroke rates remain stable over time




# In-hospital stroke rates in the Israeli multicenter registry – Stable rates




The Tel Aviv Sourasky  
Medical Center




# Procedural stroke is associated with short and intermediate term mortality




# Not all strokes are the same: Severe stroke carries higher mortality




# Not all strokes are the same: Acute stroke carries higher mortality



# The majority of strokes occur within 24 hours of TAVI



# Timing of stroke in the Israeli multicenter registry



The Tel Aviv Sourasky  
Medical Center




המרכז הרפואי  
שערי צדק







# Pathological assessment shows variable debris content




# Intervention for acute stroke has limited impact on survival




# Neuro-intervention is associated with disability-free survival at 90 days



- **79 y/o women**
- **No significant co-morbidities**
- **Underwent direct Navitor 23mm Implantation**
  
- **During access closure developed aphasia and right hemiplegia**



## Acute occlusion of LT M2



## **So what can be done to prevent stroke ?**

- **Utilization of embolic protection device?**
- **TAVI with uninterrupted OACS ?**
- **Anticoagulation post-TAVI ?**




# Cerebral protection devices in TAVI

**TriGUARD 3**

**Sentinel**

**Emboline**


**Filterlex**



# Promising early clinical data

**Sentinel IDE Trial<sup>1</sup> : 363 patients randomized 2:1 to TAVR with or without CEP**


Captured debris in  
99% of patients






# The promise of EPD

## Increased utilization in the U.S.



# PROTECTED TAVR Study Design


Patients undergoing commercial TF-TAVR  
N=3000

A rounded rectangular box with a black border contains the text 'Patients undergoing commercial TF-TAVR' and 'N=3000'. A black arrow points downwards from the bottom center of the box.


- Patients of all risk categories eligible
- Any commercially available TAVR device

# Primary End Point

## No change in stroke within 72 Hours after TAVR or before discharge (ITT Population)



# No patient subgroup benefits from Sentinel protection during TAVI



# BHF PROTECT-TAVI – awaiting results

British Heart Foundation Randomised Clinical Trial of Cerebral Embolic Protection in Transcatheter Aortic Valve Implantation (BHF PROTECT-TAVI)

Patients undergoing transfemoral TAVI (n=7730)\*

1:1 Randomisation

TAVI with CEP  
(n=3865)

TAVI without CEP  
(n=3865)

(Standardised questionnaire to assess stroke free status with mandated stroke physician review)

Primary outcome: Discharge or Stroke at 72hrs

Planned interim analysis for efficacy/futility at 50% and 70%



\* Powered for control event rate of 3% and effect size of 33%



# Identify high risk patients for stroke

## Pre-procedural parameters

- Female gender
- Prior atrial fibrillation
- Prior CABG
- Chronic pulmonary disease
- Low body mass index

## Procedural parameters


- Acute kidney injury
- Major vascular complication
- Repeated device implantation attempts
- Balloon pre-dilatation
- Balloon post-dilatation

**All studies assessed predictors for ANY stroke**

# Multicenter Transcatheter Aortic valve implantation in-hospital stroke study (TASK study)

- To identify predictors for acute stroke
- To design a simple, clinically relevant, tool to identify high-risk patients for acute stroke after TAVI

# 12 International Sites





# TASK score design

## Inclusion criteria

- All comers study
- All valve types
- Trans-femoral approach

**8,779 Patients**



## Primary end point

Stroke or TIA within 24 hours of TAVI

**127 Acute stroke events**

**1.4% of all cases**



## TASK score design

- Utilization of pre-procedural parameters
- Parameters were derived from uni- and multi-variate analysis
- Equivalent power to each TASK score parameter

# Baseline characteristics

Variable	Acute stroke N=127	No acute stroke N=8652	P value
Age (mean±SD)	82.1±6.8	83.1±6.5	0.12
Female gender	57%	52%	0.27
Low body weight*	52%	40%	<b>0.009</b>
Ischemic heart disease	31%	31%	0.95
Chronic kidney disease**	82%	68%	<b>&lt;0.001</b>
History of stroke	11%	7%	0.1
Atrial fibrillation	29%	32%	0.43
Peripheral vascular disease	29%	19%	<b>0.005</b>
Chronic lung disease	16%	17%	0.92


\* Body mass index  $\leq 25$  kg/m<sup>2</sup>

\*\* Glomerular filtration rate  $< 60$  mL/min/1.73m<sup>2</sup>





# Procedural characteristics

Variable	Acute stroke N=127	No acute stroke N=8652	P value
Conscious sedation	29%	31%	0.67
Self-expandable valve	56%	52%	0.136
Balloon expandable valve	24%	37%	<b>0.005</b>
Mechanical expandable valve	12%	6%	<b>0.001</b>
Balloon pre-dilatation	53%	50%	0.46
Balloon post-dilatation	19%	19%	0.98

# Multivariate cox regression analysis for acute stroke




# TASK score parameters


	No history of previous stroke		0 Points
	History of previous stroke		1 Point
	Normal Renal function	GFR $\geq$ 60	0 Points
	Chronic Kidney disease	GFR<60	1 Point
	Balloon Expandable Valve		0 Point
	Non-Balloon Expandable Valve		1 Point
	No Peripheral vascular disease		0 points
	Peripheral vascular disease		1 Points

TASK points	Acute stroke rate
0	0.7%
1	0.8%
2	2.1%
3	3.4%
4	7.8%

# Receiver operator curve




# Relative risk of acute stroke according to TASK score




# OAC continuation during TAVI

## Balancing the risks and benefits







# Retrospective assessment of VKA/NOAC continuation during TAVI: Study design




**Primary safety outcome was major bleeding**

# VKA / NOACS continuation during TAVI does not increase bleeding




# GALILEO trial – Post-TAVI NOACS




**No indication for AC**

# Post-TAVI OAC is harmful


Primary Efficacy Outcome



Death from Any Cause



Primary Safety Outcome



Composite of death, stroke, MI, symptomatic valve thrombosis, PE/DVT, or systemic embolism

Composite VARC life-threatening, disabling, or major bleeding.

# Summary

- **TAVI-associated strokes are rare, but devastating complication**
- **Routine use of embolic protection devices is questionable**
- **A paradigm shift to identify & target high-risk stroke patients may provide means to impact this complication**
- **OAC continuation during TAVI may prove as a safe approach**